Korean J Intern Med.
2021 Jul;36(4):975-984. 10.3904/kjim.2020.178.
Temporal evolution of programmed death-ligand 1 expression in patients with non-small cell lung cancer
- Affiliations
-
- 1Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
- 2Department of Pathology, Seoul National University Hospital, Seoul, Korea
- 3Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
- KMID: 2517814
- DOI: http://doi.org/10.3904/kjim.2020.178
Abstract
- Background/Aims
Programmed death-ligand 1 (PD-L1) expression, a validated predictive biomarker for anti-PD-1/PD-L1 inhibitors, is reported to change over time. This poses challenges during clinical application in non-small cell lung cancer.
Methods
This study included patients with non-small cell lung cancer who underwent surgery or biopsy and evaluation of PD-L1 expression in tumor cells via immunohistochemistry more than twice. We set the threshold of PD-L1 positivity to 10% and categorized patients into four groups according to changes in PD-L1 expression. Clinicopathologic information was collected from medical records. Statistical analyses, including Fisher’s exact test and log-rank test, were performed.
Results
Of 109 patients, 38 (34.9%) and 45 (41.3%) had PD-L1 positivity in archival and recent samples, respectively. PD-L1 status was maintained in 78 (71.6%) patients, but changed in 31 (28.4%), with 19 (17.4%) from negative to positive. There were no significant differences in characteristics between patients who maintained PD-L1 negativity and whose PD-L1 status changed from negative to positive. Patients harboring PD-L1 positivity in either archival or recent samples achieved better responses (p = 0.129) and showed longer overall survival than those who maintained PD-L1 negativity when they received immune checkpoint inhibitors after platinum failure (median overall survival 14.4 months vs. 4.93 months; hazard ratio, 0.43; 95% confidence interval, 0.20 to 0.93).
Conclusions
PD-L1 status changed in about one-fourth of patients. PD-L1 positivity in either archival or recent samples was predictive of better responses to immune checkpoint inhibitors. Therefore, archival samples could be used for assessment of PD-L1 status. The need for new biopsies should be decided individually.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- PD-L1 Testing in Non-small Cell Lung Cancer: Past, Present, and Future
- An update on immunotherapy with PD-1 and PD-L1 blockade
- Radiotherapy and immune checkpoint blockades: a snapshot in 2016
- Human Leukocyte Antigen Class I and Programmed Death-Ligand 1 Coexpression Is an Independent Poor Prognostic Factor in Adenocarcinoma of the Lung
- Treatment of Advanced and Metastatic Squamous Non-small Cell Lung Cancer
